iData Insights

Migraine - Pipeline Review, H2 2015 Is Released

Press Release   •   Jan 25, 2016 12:26 IST

Migraine - Pipeline Review, H2 2015 Summary Global Markets Direct s, Migraine - Pipeline Review, H2 2015, provides an overview of the Migraines therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Migraine - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Migraine and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Migraine products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Migraine pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Migraine - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Migraine pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Browsewith TOC @

To Get Sample Copy of Report visit @

Table of Contents

Introduction 9

Global Markets Direct Report Coverage 9

Migraine Overview 10

Therapeutics Development 11

Pipeline Products for Migraine - Overview 11

Pipeline Products for Migraine - Comparative Analysis 12

Migraine - Therapeutics under Development by Companies 13

Migraine - Therapeutics under Investigation by Universities/Institutes 17

Migraine - Pipeline Products Glance 18

Late Stage Products 18

Clinical Stage Products 19

Early Stage Products 20

Unknown Stage Products 21

Migraine - Products under Development by Companies 22

Migraine - Products under Investigation by Universities/Institutes 27

Migraine - Companies Involved in Therapeutics Development 28

Ache Laboratorios Farmaceuticos S/A 28

Acorda Therapeutics, Inc. 29

Afferent Pharmaceuticals, Inc. 30

Alder Biopharmaceuticals Inc. 31

Allergan Plc 32

Amgen Inc. 33

Astellas Pharma Inc. 34

BioDelivery Sciences International, Inc. 35

Biofrontera AG 36

Charleston Laboratories, Inc. 37

CoLucid Pharmaceuticals, Inc. 38

Corium International, Inc. 39

D-Pharm Ltd. 40

Eli Lilly and Company 41

iCeutica, Inc. 42

Impel NeuroPharma, Inc. 43

Mallinckrodt Plc 44

Medestea Research & Production S.p.A. 45

Merck & Co., Inc. 46

Monosol Rx, LLC 47

NAL Pharmaceuticals Ltd. 48

Nektar Therapeutics 49

Noxxon Pharma AG 50

Otsuka Holdings Co., Ltd. 51

Pantarhei Bioscience BV 52

Pivot Pharmaceuticals Inc 53

Pozen, Inc. 54

Promius Pharma, LLC 55

RedHill Biopharma Ltd. 56

Revance Therapeutics, Inc. 57

Shin Nippon Biomedical Laboratories, Ltd. 58

Suda Ltd 59

Teva Pharmaceutical Industries Limited 60

TheraJect, Inc. 61

Trevena, Inc. 62

Trigemina, Inc. 63

Vertex Pharmaceuticals Incorporated 64

Zosano Pharma Corporation 65

Migraine - Therapeutics Assessment 66

Assessment by Monotherapy Products 66

Assessment by Combination Products 67

Assessment by Target 68

Assessment by Mechanism of Action 72

Assessment by Route of Administration 75

Assessment by Molecule Type 77

Drug Profiles 79

(dextromethorphan hydrobromide + quinidine sulfate) - Drug Profile 79

(naproxen sodium + naratriptan hydrochloride) - Drug Profile 81

(sumatriptan succinate + naproxen sodium) - Drug Profile 82

(sumatriptan succinate + promethazine hydrochloride) - Drug Profile 84

AA-71 - Drug Profile 85

AF-130 - Drug Profile 86

AF-220 - Drug Profile 87

ALD-403 - Drug Profile 88

AMG-301 - Drug Profile 90

AMG-334 - Drug Profile 91

AST-003 - Drug Profile 92

BEMA Triptan - Drug Profile 93

BF-1 - Drug Profile 94

C-012 - Drug Profile 95

cloxyquin - Drug Profile 96

corticotropin - Drug Profile 97

daxibotulinumtoxin A - Drug Profile 99

Deina - Drug Profile 101

DFN-02 - Drug Profile 102

DFN-10 - Drug Profile 103

DFN-11 - Drug Profile 104

DFN-14 - Drug Profile 105

DFN-15 - Drug Profile 106

DFN-19 - Drug Profile 107

dihydroergotamine mesylate - Drug Profile 108

dihydroergotamine mesylate - Drug Profile 110

dihydroergotamine mesylate - Drug Profile 111

DORA-12 - Drug Profile 112

DP-VPA - Drug Profile 113

estetrol - Drug Profile 115

histamine dihydrochloride - Drug Profile 117

ICE-1209 - Drug Profile 118

ICE-1210 - Drug Profile 119

ICE-1211 - Drug Profile 120

ketoprofen - Drug Profile 121

lasmiditan succinate - Drug Profile 123

LY-2951742 - Drug Profile 125

MK-8031 - Drug Profile 127

NKTR-192 - Drug Profile 128

NOXL-41 - Drug Profile 129

NXN-188 - Drug Profile 130

NXN-462 - Drug Profile 131

oxytocin - Drug Profile 132

P-003 - Drug Profile 133

picotamide - Drug Profile 134

propofol hemisuccinate - Drug Profile 135

Protein to Activate Insulin Like Growth Factor 1 Receptor for Migraine - Drug Profile 136

rizatriptan benzoate - Drug Profile 137

rizatriptan benzoate - Drug Profile 139

rizatriptan benzoate - Drug Profile 140

Small Molecule to Antagonize CGRP for Migraine - Drug Profile 141

Small Molecule to Antagonize CGRP Receptor for Migraine - Drug Profile 142

Small Molecule to Antagonize Kappa Opioid Receptor for Migraine - Drug Profile 143

Small Molecule to Inhibit GABA Transaminase for Migraine and Status Epilepticus - Drug Profile 144

Small Molecule to Inhibit nNOS/NET for Migraine and Neuropathic Pain - Drug Profile 145

Small Molecules to Agonize CB2 for Chronic Pain and Migraine - Drug Profile 146

Small Molecules to Antagonize 5-HT2B for Migraine - Drug Profile 147

Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for IBS and Migraine - Drug Profile 148

Small Molecules to Inhibit CGRP for Migraine and Osteoarthritis Pain - Drug Profile 149

Small Molecules to Inhibit CGRP Receptor for Migraine - Drug Profile 150

SST-8055 - Drug Profile 151

sumatriptan succinate - Drug Profile 152

sumatriptan succinate - Drug Profile 153

sumatriptan succinate - Drug Profile 155

sumatriptan succinate - Drug Profile 157

TEV-48125 - Drug Profile 158

Tribarcina - Drug Profile 160

TRV-250 - Drug Profile 161

ubrogepant - Drug Profile 163

zolmitriptan - Drug Profile 164

zolmitriptan - Drug Profile 165

zolmitriptan - Drug Profile 166

zolmitriptan - Drug Profile 167

Migraine - Recent Pipeline Updates 168

Migraine - Dormant Projects 195

Migraine - Discontinued Products 201

Migraine - Product Development Milestones 202

Featured News & Press Releases 202

Appendix 211

Methodology 211

Coverage 211

Secondary Research 211

Primary Research 211

Expert Panel Validation 211

Contact Us 211

Disclaimer 212

Read More

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

iData Insights

Tel: 1-866-237-2965


AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects